Anbio Biotechnology (NASDAQ:NNNN) Short Interest Update

Anbio Biotechnology (NASDAQ:NNNN) saw a large increase in short interest in July. As of July 31st, there was short interest totaling 47,525 shares, an increase of 50.5% from the July 15th total of 31,583 shares. Currently, 0.0% of the company’s stock are short sold. Based on an average trading volume of 38,778 shares, the days-to-cover ratio is presently 1.2 days.

Anbio Biotechnology Price Performance

Anbio Biotechnology stock traded down $0.21 during mid-day trading on Tuesday, reaching $8.27. 51,047 shares of the company’s stock traded hands, compared to its average volume of 52,796. The stock has a 50 day moving average of $12.06 and a two-hundred day moving average of $21.04. Anbio Biotechnology has a 12-month low of $7.08 and a 12-month high of $54.50.

Wall Street Analyst Weigh In

Separately, Weiss Ratings downgraded Anbio Biotechnology from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Wednesday, July 29th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company currently has a consensus rating of “Sell”.

Anbio Biotechnology Company Profile

Anbio Biotechnology is dedicated to the advancement of medical technology and the provision of in vitro diagnostics (IVD) products. Our unwavering commitment lies in transforming the diagnostics landscape on a global scale, fostering a paradigm shift towards personalized and decentralized diagnostic solutions. By doing so, we aim to significantly enhance patient prognosis and contribute to the betterment of healthcare worldwide. At Anbio Biotechnology, our extensive portfolio comprises an array of IVD products designed to cater to diverse diagnostic needs.